-

$undefined

N/A

(N/A)

Acelyrin Inc. NasdaqGS:SLRN Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California. As of May 21, 2025, Acelyrin, Inc. operates as a subsidiary of Alumis Inc.

Location: 4149 Liberty Canyon Road, Agoura Hills, CA, 91301, United States | Website: https://www.acelyrin.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-174.4M

Cash

410.6M

Avg Qtr Burn

-71.39M

Short % of Float

5.21%

Insider Ownership

7.15%

Institutional Own.

91.98%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lonigutamab Details
Thyroid Eye Disease , Eye disease

Phase 3

Initiation

Izokibep Details
Axial spondyloarthritis

Failed

Discontinued

Izokibep Details
Psoriatic arthritis

Failed

Discontinued

SLRN-517 Details
Allergy, Inflammatory disease, KIT/Mast cell diseases

Failed

Discontinued

Izokibep Details
Uveitis , Eye disease

Failed

Discontinued

Izokibep Details
Hidradenitis suppurativa

Failed

Discontinued